SCHEMBL144114

SCHEMBL144114

Cc1cc(C(=O)NCCCn2ccnn2)c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4ccccc4)cc32)[nH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 2/20 0.44
PDGFRB P09619 6/20 0.43
KDR P35968 6/20 0.43
PDGFRA P16234 3/20 0.43
GRK5 P34947 1/20 0.39
SRC P12931 7/20 0.39
PAK4 O96013 1/20 0.39
FGFR1 P11362 5/20 0.39
LCK P06239 3/20 0.39
YES1 P07947 3/20 0.39
FYN P06241 2/20 0.39
FLT1 P17948 1/20 0.37
EGFR P00533 2/20 0.37
PRKAA2 P54646 2/20 0.37
PRKAA1 Q13131 2/20 0.37
LRRK2 Q5S007 1/20 0.37
RET P07949 2/20 0.37
PRKDC P78527 1/20 0.37
PLK4 O00444 1/20 0.37
RIOK3 O14730 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL142865 0.93 KDR (0.41) AURKAPDGFRBKDRPDGFRAGRK5
SCHEMBL146649 0.91 PDGFRB (0.41) AURKAPDGFRBKDRPDGFRASRC
SCHEMBL143687 0.87 SRC (0.49) AURKAPDGFRBKDRPDGFRASRC
SCHEMBL144568 0.85 KDR (0.55) AURKAPDGFRBKDRPDGFRAGRK5
SCHEMBL6519857 0.80 AURKA (0.56) AURKAPDGFRBKDRPDGFRASRC
SCHEMBL143213 0.80 SRC (0.48) PDGFRBKDRPDGFRASRCFGFR1
SCHEMBL145496 0.78 SRC (0.47) AURKAPDGFRBKDRPDGFRASRC
SCHEMBL145575 0.78 PDGFRB (0.50) PDGFRBKDRPDGFRASRCFGFR1
SCHEMBL144561 0.76 PDGFRB (0.56) AURKAPDGFRBKDRPDGFRAGRK5
SCHEMBL141995 0.75 RET (0.61) AURKAPDGFRBKDRPDGFRASRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR VERVA PHARMACEUTICALS PTY LTD (AU) 2012-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR FGF1, FABP4, FGF2 AURKA 4579/4885PDGFRB 467/4885KDR 1077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.